Letrozole - Revision history

Lazy at 08:23, 18 January 2025

2025-01-18T08:23:40Z

← Older revision		Revision as of 01:23, 18 January 2025
Line 15:		Line 15:
	\|treatment_category=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|toxicity_explanation=The treatment's toxicity level is rated at 2.5 out of a possible 5. This suggests that the treatment has some side effects, which can include hot flashes, joint pain, nausea, an increased risk of osteoporosis, and fatigue. However, these side effects are typically manageable and are considered moderate in comparison to other treatments. It's important to note that these side effects may not be experienced by everyone and can vary in intensity from person to person. Also, this drug is still in the experimental phase for glioblastoma and is not yet specifically approved for this type of brain cancer. The exact toxicity could change as more research is done.		\|toxicity_explanation=The treatment's toxicity level is rated at 2.5 out of a possible 5. This suggests that the treatment has some side effects, which can include hot flashes, joint pain, nausea, an increased risk of osteoporosis, and fatigue. However, these side effects are typically manageable and are considered moderate in comparison to other treatments. It's important to note that these side effects may not be experienced by everyone and can vary in intensity from person to person. Also, this drug is still in the experimental phase for glioblastoma and is not yet specifically approved for this type of brain cancer. The exact toxicity could change as more research is done.
	}}		\|overview=Letrozole is an FDA-approved drug primarily used for hormone receptor-positive breast cancer, currently undergoing a Phase 2 clinical trial to assess its effectiveness in treating glioblastoma. While it has moderate side effects and is considered under investigation, early studies suggest potential benefits in repurposing this breast cancer treatment to inhibit glioblastoma cell growth through estrogen receptor targeting.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:36:47Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:36, 12 November 2024
Line 13:		Line 13:
	\|notes=A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients.		\|notes=A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients.
	\|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)		\|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|toxicity_explanation=The treatment's toxicity level is rated at 2.5 out of a possible 5. This suggests that the treatment has some side effects, which can include hot flashes, joint pain, nausea, an increased risk of osteoporosis, and fatigue. However, these side effects are typically manageable and are considered moderate in comparison to other treatments. It's important to note that these side effects may not be experienced by everyone and can vary in intensity from person to person. Also, this drug is still in the experimental phase for glioblastoma and is not yet specifically approved for this type of brain cancer. The exact toxicity could change as more research is done.		\|toxicity_explanation=The treatment's toxicity level is rated at 2.5 out of a possible 5. This suggests that the treatment has some side effects, which can include hot flashes, joint pain, nausea, an increased risk of osteoporosis, and fatigue. However, these side effects are typically manageable and are considered moderate in comparison to other treatments. It's important to note that these side effects may not be experienced by everyone and can vary in intensity from person to person. Also, this drug is still in the experimental phase for glioblastoma and is not yet specifically approved for this type of brain cancer. The exact toxicity could change as more research is done.
	}}		}}

Lazy at 16:56, 27 March 2024

2024-03-27T16:56:37Z

← Older revision		Revision as of 09:56, 27 March 2024
Line 14:		Line 14:
	\|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)		\|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
			\|toxicity_explanation=The treatment's toxicity level is rated at 2.5 out of a possible 5. This suggests that the treatment has some side effects, which can include hot flashes, joint pain, nausea, an increased risk of osteoporosis, and fatigue. However, these side effects are typically manageable and are considered moderate in comparison to other treatments. It's important to note that these side effects may not be experienced by everyone and can vary in intensity from person to person. Also, this drug is still in the experimental phase for glioblastoma and is not yet specifically approved for this type of brain cancer. The exact toxicity could change as more research is done.
	}}		}}

Lazy at 06:06, 27 March 2024

2024-03-27T06:06:20Z

← Older revision		Revision as of 23:06, 26 March 2024
Line 13:		Line 13:
	\|notes=A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients.		\|notes=A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients.
	\|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)		\|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)
	\|category=~~Experimental Treatments~~		\|category=Repurposed Drugs
	}}		}}

Lazy at 06:05, 27 March 2024

2024-03-27T06:05:55Z

← Older revision		Revision as of 23:05, 26 March 2024
Line 1:		Line 1:
	{		{{TreatmentInfo
	"drug_name~~": "~~Letrozole",		\|drug_name=Letrozole
	"FDA_approval~~": "~~Yes, for breast cancer; not ~~FDA-~~approved for ~~glioblastoma",~~		\|FDA_approval=Yes (approved for breast cancer; not specifically approved for brain cancer yet)
	"used_for~~": "Investigational use in~~ glioblastoma ~~based on preclinical studies",~~		\|used_for=Experimental for glioblastoma; approved for hormone receptor-positive breast cancer
	"clinical_trial_phase~~": "Preclinical studies and early research for glioblastoma",~~		\|clinical_trial_phase=Phase 2
	"common_side_effects~~": "~~Hot flashes, joint pain, nausea, ~~fatigue, and~~ risk of osteoporosis",		\|common_side_effects=Hot flashes, joint pain, nausea, increased risk of osteoporosis, fatigue
	"OS_with~~": "~~Not ~~available; research in glioblastoma is still in early stages",~~		\|OS_with=Not specified
	"PFS_with~~": "~~Not ~~available; research in glioblastoma is still in early stages",~~		\|OS_without=Not specified
	"usefulness_rating~~": "~~2 ~~(based on early research potential, awaiting clinical trial outcomes for glioblastoma)",~~		\|PFS_with=Not specified
	~~"toxicity_level": "~~2 ~~(relatively low in~~ the ~~context~~ of ~~its approved use for~~ breast cancer, ~~with common manageable side effects)",~~		\|PFS_without=Not specified
	~~"notes": "~~Letrozole, ~~a drug commonly~~ used in breast cancer ~~treatment~~, ~~has shown potential in preclinical studies for treating~~ glioblastoma by targeting estrogen receptors~~, which are implicated in some glioblastoma cell growth~~. ~~Further research~~, ~~including clinical trials~~, ~~is necessary to fully understand its efficacy~~ and ~~safety profile~~ in glioblastoma patients.",		\|usefulness_rating=3 - Under investigation
	~~"category"~~: ~~"Repurposed Drugs"~~,		\|toxicity_level=2.5
	~~"links": "~~https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/"		\|notes=A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients.
	}		\|links=[University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)
			\|category=Experimental Treatments
			}}

Lazy: Created page with "{ "drug_name": "Letrozole", "FDA_approval": "Yes, for breast cancer; not FDA-approved for glioblastoma", "used_for": "Investigational use in glioblastoma based on preclinical studies", "clinical_trial_phase": "Preclinical studies and early research for glioblastoma", "common_side_effects": "Hot flashes, joint pain, nausea, fatigue, and risk of osteoporosis", "OS_with": "Not available; research in glioblastoma is still in early stages", "PFS_with": "Not avai..."

2024-03-27T05:49:48Z

Created page with "{ "drug_name": "Letrozole", "FDA_approval": "Yes, for breast cancer; not FDA-approved for glioblastoma", "used_for": "Investigational use in glioblastoma based on preclinical studies", "clinical_trial_phase": "Preclinical studies and early research for glioblastoma", "common_side_effects": "Hot flashes, joint pain, nausea, fatigue, and risk of osteoporosis", "OS_with": "Not available; research in glioblastoma is still in early stages", "PFS_with": "Not avai..."

New page

{
"drug_name": "Letrozole",
"FDA_approval": "Yes, for breast cancer; not FDA-approved for glioblastoma",
"used_for": "Investigational use in glioblastoma based on preclinical studies",
"clinical_trial_phase": "Preclinical studies and early research for glioblastoma",
"common_side_effects": "Hot flashes, joint pain, nausea, fatigue, and risk of osteoporosis",
"OS_with": "Not available; research in glioblastoma is still in early stages",
"PFS_with": "Not available; research in glioblastoma is still in early stages",
"usefulness_rating": "2 (based on early research potential, awaiting clinical trial outcomes for glioblastoma)",
"toxicity_level": "2 (relatively low in the context of its approved use for breast cancer, with common manageable side effects)",
"notes": "Letrozole, a drug commonly used in breast cancer treatment, has shown potential in preclinical studies for treating glioblastoma by targeting estrogen receptors, which are implicated in some glioblastoma cell growth. Further research, including clinical trials, is necessary to fully understand its efficacy and safety profile in glioblastoma patients.",
"category": "Repurposed Drugs",
"links": "https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/"
}